NASHVILLE, Tenn. (AP) -- Tennessee will receive $1.95 million coming from a multistate settlement between a giant pharmaceutical company accused of deceptively marketing the anti-seizure drug Depakote.

The state's cut was part of a $100 million agreement between 45 states and the District of Columbia and Abbott Laboratories. The agreement is the largest consumer protection-based pharmaceutical settlement ever reached.

The states accused the pharmaceutical company of engaging in deceptive marketing practices when it marketed Depakote for off-label uses. Depakote has been approved for the treatment of seizures, migraine headaches and mania associated with bipolar disorder. The states said the company marketed the drug to treat medical issues where the drug has not been approved, such as schizophrenia, agitated dementia and autism.